DK0469065T3 - Rekombinant antistof-toxin fusionsprotein - Google Patents

Rekombinant antistof-toxin fusionsprotein

Info

Publication number
DK0469065T3
DK0469065T3 DK90907767.9T DK90907767T DK0469065T3 DK 0469065 T3 DK0469065 T3 DK 0469065T3 DK 90907767 T DK90907767 T DK 90907767T DK 0469065 T3 DK0469065 T3 DK 0469065T3
Authority
DK
Denmark
Prior art keywords
toxin fusion
fusion protein
antibody toxin
recombinant antibody
tac
Prior art date
Application number
DK90907767.9T
Other languages
English (en)
Inventor
Thomas A Waldmann
Ira H Pastan
David J Fitzgerald
Vijay Kumar Chaudhary
Cary L Queen
Original Assignee
Protein Design Labs Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc, Us Health filed Critical Protein Design Labs Inc
Application granted granted Critical
Publication of DK0469065T3 publication Critical patent/DK0469065T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6829Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK90907767.9T 1989-04-21 1990-04-20 Rekombinant antistof-toxin fusionsprotein DK0469065T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34136189A 1989-04-21 1989-04-21

Publications (1)

Publication Number Publication Date
DK0469065T3 true DK0469065T3 (da) 1996-07-15

Family

ID=23337235

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90907767.9T DK0469065T3 (da) 1989-04-21 1990-04-20 Rekombinant antistof-toxin fusionsprotein

Country Status (10)

Country Link
EP (1) EP0469065B1 (da)
JP (1) JPH0829101B2 (da)
AT (1) ATE138688T1 (da)
AU (1) AU641392B2 (da)
CA (1) CA2053911C (da)
DE (1) DE69027210T2 (da)
DK (1) DK0469065T3 (da)
ES (1) ES2091824T3 (da)
IL (1) IL94159A0 (da)
WO (1) WO1990012592A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
DE69025211T2 (de) * 1989-02-17 1996-09-19 Merck & Co Inc Protein-Antikrebsmittel
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
WO1993007286A1 (en) * 1991-09-30 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Recombinant immunotoxins
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Il−2受容体重鎖に結合するポリペプチド
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5840854A (en) * 1995-10-19 1998-11-24 Bristol-Myers Squibb Company Monoclonal antibody BR110 and uses thereof
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
IL129474A0 (en) * 1996-10-23 2000-02-29 Univ Wake Forest Targeted cytotoxic cells
PL2631248T3 (pl) 2007-06-15 2018-06-29 Medigene Ag Leczenie nowotworów z użyciem specyficznego przeciwciała anty-L1
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
MX388698B (es) 2014-09-30 2025-03-20 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP3559039A1 (en) 2016-12-22 2019-10-30 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003971A1 (en) * 1982-05-12 1983-11-24 President And Fellows Of Harvard College Hybrid proteins
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
DE69025211T2 (de) * 1989-02-17 1996-09-19 Merck & Co Inc Protein-Antikrebsmittel

Also Published As

Publication number Publication date
IL94159A0 (en) 1991-01-31
JPH0829101B2 (ja) 1996-03-27
CA2053911A1 (en) 1990-10-22
EP0469065B1 (en) 1996-05-29
AU641392B2 (en) 1993-09-23
WO1990012592A1 (en) 1990-11-01
ES2091824T3 (es) 1996-11-16
AU5562790A (en) 1990-11-16
JPH04504363A (ja) 1992-08-06
DE69027210T2 (de) 1997-01-23
CA2053911C (en) 1999-11-02
EP0469065A1 (en) 1992-02-05
ATE138688T1 (de) 1996-06-15
DE69027210D1 (de) 1996-07-04
EP0469065A4 (en) 1992-07-08

Similar Documents

Publication Publication Date Title
DE69027210D1 (de) Rekombinantes antikörper-toxin-fusion-protein
BR9507594B1 (pt) anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteìna recombinante.
NO885326L (no) Human vevfaktor-beslektede dna-segmenter, polypeptider ogantistoffer.
DE69228701D1 (de) Fragmente von Prion Proteinen.
UA41888C2 (uk) Злитий білок, який складається з мишачого або олюдненого моноклонального антитіла мав425 або його фрагменту, який спрямовано проти пухлинної клітини, спосіб його отримання, фармацевтична композиція
TR199902426T2 (xx) Bitki b�ceklerinin kontrol�.
PT778891E (pt) Anticorpo monoclonal recombinante anti-rhesus d (d7c2)
DE3382837T2 (de) Herstellung von funktionellen, menschlichen Urokinaseproteinen
ATE171596T1 (de) Neue gegen phtiraptera aktive bcillus thuringiensis isolate
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
BR9606889A (pt) Toxinas proteicas inseticidas de photorhabdus
DE602004013372D1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
DK1887014T3 (da) Humane Toll-homologer
ES552534A0 (es) Un metodo para obtener un polipeptido complementario de al menos una porcion de un peptido o proteina original.
ES2085993T3 (es) Proteina asociada a la pancreatitis aguda, medios para el diagnostico de la pancreatitis aguda.
DE59708952D1 (de) Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen
ATE160575T1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
DE69630008D1 (de) Treponema palladium Fusions-Antigen, Nachweis für Anti-treponema palladium Antikörpern mit diesen Fusions-Antigenen
PT625157E (pt) Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
ATE97959T1 (de) Monoklonale antikoerper gegen menschliche alphaatrialnatri¨retic-polypeptide und entsprechende hybridome, deren herstellung und verwendung.
KR100315596B1 (ko) 인간의 자연형 IgM 항체
ES2067501T3 (es) Antigeno recombinante de treponema hyodysenteriae y sus usos.